Diversified Consumer Services
Company Overview of The University of Chicago
The University of Chicago is an educational institution that offers undergraduate, graduate, and professional programs in the fields of biology, humanity, law, social service, and physical science. The schools of the university include Divinity School, Booth School of Business, Graham School of General Studies, Harris Graduate School of Public Policy Studies, Law School, Pritzker School of Medicine, and School of Social Service Administration. The University of Chicago was founded in 1890 and is based in Chicago, Illinois. It has endowment assets of $3963.4 millions.
5801 South Ellis Avenue
Chicago, IL 60637-5418
Founded in 1890
Key Executives for The University of Chicago
Vice President for Administration and Chief Financial Officer
Adjunct Professor of Finance
Compensation as of Fiscal Year 2016.
The University of Chicago Key Developments
The University of Chicago Department of Pediatrics Presents at Sachs Associates 2nd Annual Immune-Oncology BD&L and Investment Forum, Jun-03-2016 05:00 PM
May 31 16
The University of Chicago Department of Pediatrics Presents at Sachs Associates 2nd Annual Immune-Oncology BD&L and Investment Forum, Jun-03-2016 05:00 PM. Venue: Hyatt Chicago Magnificent Mile, 633 North Saint Clair Street, Chicago, IL 60611, United States. Speakers: Rena Conti, Assistant Professor Hematology/Oncology.
twoXAR, Inc. Enters Research Collaboration with Department of Medicine at University of Chicago
May 25 16
twoXAR Inc. announced a collaboration with the Department of Medicine at the University of Chicago focused on the identification and investigation of potential new medicines for treating atherosclerosis. As part of this collaboration, twoXAR will use its disease-to-candidate prediction software to integrate and analyze diverse biomedical data sets to predict efficacious drug candidates for in vivo testing. Researchers at the University of Chicago will test the effectiveness of predicted drug candidates in promoting vascular endothelial health and in preventing atherosclerosis. Cultured endothelial cells treated with the predicted molecules will be stimulated by tumor necrosis factor alpha (TNFa) in vitro followed by in vivo testing in animal models of atherosclerosis. twoXAR will provide scientific expertise to assist the Department of Medicine at the University of Chicago in the selection and delivery of candidates for pre-clinical study.
AbbVie and University of Chicago Collaborate to Advance Cancer Research
Apr 20 16
The University of Chicago and AbbVie entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in oncology at both organizations. The joint strategic research agreement between AbbVie and the University of Chicago is designed to encourage and strengthen collaboration among researchers. Initially, both organizations will work together to advance research in several areas of oncology, which could include, among others, breast, lung, prostate, colorectal and hematological cancer. Research projects are chosen by a joint steering committee, comprised of representatives from each organization. AbbVie also gains an option for an exclusive license to certain University of Chicago discoveries made under the agreement. As part of the agreement, AbbVie will provide funding for the collaboration that may be used for purposes including preclinical research, clinical trials and possible future programs at the University resulting from this partnership. The overall collaborative efforts will provide University of Chicago physicians and scientists with the opportunity to participate in AbbVie-sponsored clinical trials, access to new therapies developed by AbbVie for use in preclinical research funded under the collaboration, as well as opportunities to work closely with AbbVie's research and development teams to promote scientific knowledge exchange. As part of the collaborative agreement, researchers from the University of Chicago and AbbVie will participate in an annual symposium that brings together scientists from both institutions to discuss research and evaluate potential new projects. Collaborative efforts also provide AbbVie researchers with access to data commons technology developed by the Center for Data Intensive Science at the University of Chicago and the core technical team that is developing the technology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|